CN101641339B - 用于预防和治疗心血管疾病的化合物 - Google Patents
用于预防和治疗心血管疾病的化合物 Download PDFInfo
- Publication number
- CN101641339B CN101641339B CN2007800523498A CN200780052349A CN101641339B CN 101641339 B CN101641339 B CN 101641339B CN 2007800523498 A CN2007800523498 A CN 2007800523498A CN 200780052349 A CN200780052349 A CN 200780052349A CN 101641339 B CN101641339 B CN 101641339B
- Authority
- CN
- China
- Prior art keywords
- dimethoxy
- ketone
- ethyl
- dihydroquinazoline
- oxo
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Active
Links
- 0 CC(C*(C)C*(*)**=[N+][O-])*(C)* Chemical compound CC(C*(C)C*(*)**=[N+][O-])*(C)* 0.000 description 4
- SQBKNGXWWBLWCX-UHFFFAOYSA-N COc(c(OC)c1)cc2c1N=C(c(cc1)ccc1N(CCO)CCO)NC2=O Chemical compound COc(c(OC)c1)cc2c1N=C(c(cc1)ccc1N(CCO)CCO)NC2=O SQBKNGXWWBLWCX-UHFFFAOYSA-N 0.000 description 1
- KTACWZKZFWVPAU-UHFFFAOYSA-N COc(cc1OC)cc(N=C(c(cc2)ccc2N(CCO)CCO)N2)c1C2=O Chemical compound COc(cc1OC)cc(N=C(c(cc2)ccc2N(CCO)CCO)N2)c1C2=O KTACWZKZFWVPAU-UHFFFAOYSA-N 0.000 description 1
- WPYMKLBDIGXBTP-UHFFFAOYSA-N OC(c1ccccc1)=O Chemical compound OC(c1ccccc1)=O WPYMKLBDIGXBTP-UHFFFAOYSA-N 0.000 description 1
Images
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
- A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
- A61K31/517—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim ortho- or peri-condensed with carbocyclic ring systems, e.g. quinazoline, perimidine
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/4353—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom ortho- or peri-condensed with heterocyclic ring systems
- A61K31/4375—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom ortho- or peri-condensed with heterocyclic ring systems the heterocyclic ring system containing a six-membered ring having nitrogen as a ring heteroatom, e.g. quinolizines, naphthyridines, berberine, vincamine
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/47—Quinolines; Isoquinolines
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/47—Quinolines; Isoquinolines
- A61K31/472—Non-condensed isoquinolines, e.g. papaverine
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
- A61K31/496—Non-condensed piperazines containing further heterocyclic rings, e.g. rifampin, thiothixene
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
- A61K31/4965—Non-condensed pyrazines
- A61K31/497—Non-condensed pyrazines containing further heterocyclic rings
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
- A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
- A61K31/519—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim ortho- or peri-condensed with heterocyclic rings
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/535—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with at least one nitrogen and one oxygen as the ring hetero atoms, e.g. 1,2-oxazines
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/535—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with at least one nitrogen and one oxygen as the ring hetero atoms, e.g. 1,2-oxazines
- A61K31/5375—1,4-Oxazines, e.g. morpholine
- A61K31/5377—1,4-Oxazines, e.g. morpholine not condensed and containing further heterocyclic rings, e.g. timolol
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/54—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with at least one nitrogen and one sulfur as the ring hetero atoms, e.g. sulthiame
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/695—Silicon compounds
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61L—METHODS OR APPARATUS FOR STERILISING MATERIALS OR OBJECTS IN GENERAL; DISINFECTION, STERILISATION OR DEODORISATION OF AIR; CHEMICAL ASPECTS OF BANDAGES, DRESSINGS, ABSORBENT PADS OR SURGICAL ARTICLES; MATERIALS FOR BANDAGES, DRESSINGS, ABSORBENT PADS OR SURGICAL ARTICLES
- A61L29/00—Materials for catheters, medical tubing, cannulae, or endoscopes or for coating catheters
- A61L29/14—Materials characterised by their function or physical properties, e.g. lubricating compositions
- A61L29/16—Biologically active materials, e.g. therapeutic substances
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61L—METHODS OR APPARATUS FOR STERILISING MATERIALS OR OBJECTS IN GENERAL; DISINFECTION, STERILISATION OR DEODORISATION OF AIR; CHEMICAL ASPECTS OF BANDAGES, DRESSINGS, ABSORBENT PADS OR SURGICAL ARTICLES; MATERIALS FOR BANDAGES, DRESSINGS, ABSORBENT PADS OR SURGICAL ARTICLES
- A61L31/00—Materials for other surgical articles, e.g. stents, stent-grafts, shunts, surgical drapes, guide wires, materials for adhesion prevention, occluding devices, surgical gloves, tissue fixation devices
- A61L31/14—Materials characterised by their function or physical properties, e.g. injectable or lubricating compositions, shape-memory materials, surface modified materials
- A61L31/16—Biologically active materials, e.g. therapeutic substances
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/06—Antihyperlipidemics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D217/00—Heterocyclic compounds containing isoquinoline or hydrogenated isoquinoline ring systems
- C07D217/22—Heterocyclic compounds containing isoquinoline or hydrogenated isoquinoline ring systems with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to carbon atoms of the nitrogen-containing ring
- C07D217/24—Oxygen atoms
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D239/00—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings
- C07D239/70—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings condensed with carbocyclic rings or ring systems
- C07D239/72—Quinazolines; Hydrogenated quinazolines
- C07D239/86—Quinazolines; Hydrogenated quinazolines with hetero atoms directly attached in position 4
- C07D239/88—Oxygen atoms
- C07D239/91—Oxygen atoms with aryl or aralkyl radicals attached in position 2 or 3
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D279/00—Heterocyclic compounds containing six-membered rings having one nitrogen atom and one sulfur atom as the only ring hetero atoms
- C07D279/02—1,2-Thiazines; Hydrogenated 1,2-thiazines
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
- C07D401/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
- C07D401/04—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings directly linked by a ring-member-to-ring-member bond
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D403/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00
- C07D403/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings
- C07D403/12—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings linked by a chain containing hetero atoms as chain links
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D405/00—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom
- C07D405/02—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings
- C07D405/04—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings directly linked by a ring-member-to-ring-member bond
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D413/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms
- C07D413/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings
- C07D413/06—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings linked by a carbon chain containing only aliphatic carbon atoms
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D471/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00
- C07D471/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00 in which the condensed system contains two hetero rings
- C07D471/04—Ortho-condensed systems
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07F—ACYCLIC, CARBOCYCLIC OR HETEROCYCLIC COMPOUNDS CONTAINING ELEMENTS OTHER THAN CARBON, HYDROGEN, HALOGEN, OXYGEN, NITROGEN, SULFUR, SELENIUM OR TELLURIUM
- C07F7/00—Compounds containing elements of Groups 4 or 14 of the Periodic System
- C07F7/02—Silicon compounds
- C07F7/08—Compounds having one or more C—Si linkages
- C07F7/18—Compounds having one or more C—Si linkages as well as one or more C—O—Si linkages
- C07F7/1804—Compounds having Si-O-C linkages
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61L—METHODS OR APPARATUS FOR STERILISING MATERIALS OR OBJECTS IN GENERAL; DISINFECTION, STERILISATION OR DEODORISATION OF AIR; CHEMICAL ASPECTS OF BANDAGES, DRESSINGS, ABSORBENT PADS OR SURGICAL ARTICLES; MATERIALS FOR BANDAGES, DRESSINGS, ABSORBENT PADS OR SURGICAL ARTICLES
- A61L2300/00—Biologically active materials used in bandages, wound dressings, absorbent pads or medical devices
- A61L2300/20—Biologically active materials used in bandages, wound dressings, absorbent pads or medical devices containing or releasing organic materials
- A61L2300/204—Biologically active materials used in bandages, wound dressings, absorbent pads or medical devices containing or releasing organic materials with nitrogen-containing functional groups, e.g. aminoxides, nitriles, guanidines
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61L—METHODS OR APPARATUS FOR STERILISING MATERIALS OR OBJECTS IN GENERAL; DISINFECTION, STERILISATION OR DEODORISATION OF AIR; CHEMICAL ASPECTS OF BANDAGES, DRESSINGS, ABSORBENT PADS OR SURGICAL ARTICLES; MATERIALS FOR BANDAGES, DRESSINGS, ABSORBENT PADS OR SURGICAL ARTICLES
- A61L2300/00—Biologically active materials used in bandages, wound dressings, absorbent pads or medical devices
- A61L2300/60—Biologically active materials used in bandages, wound dressings, absorbent pads or medical devices characterised by a special physical form
- A61L2300/606—Coatings
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61L—METHODS OR APPARATUS FOR STERILISING MATERIALS OR OBJECTS IN GENERAL; DISINFECTION, STERILISATION OR DEODORISATION OF AIR; CHEMICAL ASPECTS OF BANDAGES, DRESSINGS, ABSORBENT PADS OR SURGICAL ARTICLES; MATERIALS FOR BANDAGES, DRESSINGS, ABSORBENT PADS OR SURGICAL ARTICLES
- A61L2420/00—Materials or methods for coatings medical devices
Abstract
Description
实施例 编号 | 化合物名称 | 对ApoA-I mRNA水 平的作用 |
38 | 3-(2-(4-(5,7-二甲氧基-4-氧代-3,4-二氢喹唑啉-2- 基)-2,6-二甲基苯氧基)乙基)-1,1-二甲基脲 | 活性 |
37 | 1-(2-(4-(5,7-二甲氧基-4-氧代-3,4-二氢喹唑啉-2- 基)-2,6-二甲基苯氧基)乙基)-3-苯基脲 | 活性 |
36 | 1-(2-(4-(5,7-二甲氧基-4-氧代-3,4-二氢喹唑啉-2- 基)-2,6-二甲基苯氧基)乙基)-3-(4-甲氧基苯基)脲 | 活性 |
实施例 编号 | 化合物名称 | 对ApoA-I mRNA水 平的作用 |
35 | 1-(2-(4-(5,7-二甲氧基-4-氧代-3,4-二氢喹唑啉-2- 基)-2,6-二甲基苯氧基)乙基)-3-甲基脲 | 活性 |
34 | N-(2-(4-(5,7-二甲氧基-4-氧代-3,4-二氢喹唑啉-2- 基)-2,6-二甲基苯氧基)乙基)异丁酰胺 | 活性 |
33 | N-(2-(4-(5,7-二甲氧基-4-氧代-3,4-二氢喹唑啉-2- 基)-2,6-二甲基苯氧基)乙基)苯甲酰胺 | 活性 |
32 | N-(2-(4-(5,7-二甲氧基-4-氧代-3,4-二氢喹唑啉-2- 基)-2,6-二甲基苯氧基)乙基)乙酰胺 | 活性 |
31 | N-(2-(4-(5,7-二甲氧基-4-氧代-3,4-二氢喹唑啉-2- 基)-2,6-二甲基苯氧基)乙基)-4-甲氧基苯甲酰胺 | 活性 |
30 | N-(2-(4-(5,7-二甲氧基-4-氧代-3,4-二氢喹唑啉-2- 基)-2,6-二甲基苯氧基)乙基)-4-甲基苯磺酰胺 | 活性 |
29 | N-(2-(4-(5,7-二甲氧基-4-氧代-3,4-二氢喹唑啉-2- 基)-2,6-二甲基苯氧基)乙基)苯磺酰胺 | 活性 |
28 | 环己基氨甲酸2-(4-(5,7-二甲氧基-4-氧代-3,4-二氢喹 唑啉-2-基)-2,6-二甲基苯氧基)乙基酯 | 活性 |
27 | N-(2-(4-(5,7-二甲氧基-4-氧代-3,4-二氢喹唑啉-2- 基)-2,6-二甲基苯氧基)乙基)-4-甲基苯甲酰胺 | 活性 |
26 | 甲基氨甲酸2-(4-(5,7-二甲氧基-4-氧代-3,4-二氢喹唑 啉-2-基)-2,6-二甲基-苯氧基)乙基酯 | 活性 |
25 | 丙基氨甲酸2-(4-(5,7-二甲氧基-4-氧代-3,4-二氢喹唑 啉-2-基)-2,6-二甲基-苯氧基)乙基酯 | 活性 |
24 | N-(2-(4-(5,7-二甲氧基-4-氧代-3,4-二氢喹唑啉-2- 基)-2,6-二甲基苯氧基)乙基)甲磺酰胺 | 活性 |
实施例 编号 | 化合物名称 | 对ApoA-I mRNA水 平的作用 |
23 | 4-氯-N-(2-(4-(5,7-二甲氧基-4-氧代-3,4-二氢喹唑啉-2- 基)-2,6-二甲基苯氧基)乙基)苯磺酰胺 | 活性 |
22 | N-(2-(4-(5,7-二甲氧基-4-氧代-3,4-二氢喹唑啉-2- 基)-2,6-二甲基苯氧基)乙基)-4-甲氧基苯磺酰胺 | 活性 |
21 | N1-(2-(4-(5,7-二甲氧基-4-氧代-3,4-二氢喹唑啉-2- 基)-2,6-二甲基苯氧基)乙基)-N2-甲基邻苯二甲酰胺 | 活性 |
20 | 4-氯-N-(2-(4-(5,7-二甲氧基-4-氧代-3,4-二氢喹唑啉-2- 基)-2,6-二甲基苯氧基)乙基)苯磺酰胺 | 活性 |
18 | 2-(4-(2-氨基乙氧基)-3,5-二甲基苯基)-5,7-二甲氧基喹 唑啉-4(3H)-酮 | 活性 |
18 | N1-(2-(4-(5,7-二甲氧基-4-氧代-3,4-二氢喹唑啉-2- 基)-2,6-二甲基苯氧基)乙基)-N2-甲基邻苯二甲酰胺 | 活性 |
17 | 2-(4-氨基-3,5-二甲基苯基)-5,7-二甲氧基喹唑啉 -4(3H)-酮 | 活性 |
16 | 5,7-二甲氧基-2-(4-甲氧基-3,5-二甲基苯基)喹唑啉 -4(3H)-酮 | 活性 |
15 | 2-(2-氯-6-甲基吡啶-4-基)-5,7-二甲氧基喹唑啉-4(3H)- 酮 | 活性 |
14 | 2-(4-(2-羟基乙氧基)-3,5-二甲基苯基)-5,7-二甲氧基吡 啶并[2,3-d]嘧啶-4(3H)-酮 | 活性 |
13 | 2-(4-((4-乙基哌嗪-1-基)甲基)苯基)-5,7-二甲氧基喹唑 啉-4(3H)-酮 | 活性 |
12 | 2-(2,3-二氢苯并[b][1,4]二噁烯-6-基)-6,7-二甲氧基喹 唑啉-4(3H)-酮 | 活性 |
实施例 编号 | 化合物名称 | 对ApoA-I mRNA水 平的作用 |
11 | 2-(4-(双(2-羟基乙基)氨基)苯基)-6,7-二甲氧基喹唑啉 -4(3H)-酮 | 活性 |
10 | 2-(4-(双(2-羟基乙基)氨基)苯基)-5,7-二甲氧基喹唑啉 -4(3H)-酮 | 活性 |
9 | 2-(4-羟基-3-甲氧基苯基)-5,7-二甲氧基喹唑啉-4(3H)- 酮 | 活性 |
8 | 3-(3,5-二甲基-4-(2-(4-甲基哌嗪-1-基)乙氧基)苯 基)-6,8-二甲氧基异喹啉-1(2H)-酮 | 活性 |
7 | 2-(4-(2-羟基乙氧基)-3,5-二甲基苯基)-5,7-二甲氧基喹 唑啉-4(3H)-酮 | 活性 |
6 | 7-(4-羟基-3,5-二甲基苯基)-2,4-二甲氧基-1,6-萘啶 -5(6H)-酮 | 活性 |
5 | 3-(4-(2-羟基-2-甲基丙氧基)-3,5-二甲基苯基)-6,8-二 甲氧基异喹啉-1(2H)-酮 | 活性 |
4 | 2-(4-羟基-3,5-二甲基苯基)-5,7-二甲氧基喹唑啉 -4(3H)-酮 | 活性 |
3 | 3-(4-羟基-3,5-二甲基苯基)-7-(吗啉代基甲基)异喹啉 -1(2H)-酮 | 活性 |
2 | 3-(4-(2-羟基乙氧基)-3,5-二甲基苯基)-6,8-二甲氧基异 喹啉-1(2H)-酮 | 活性 |
1 | 3-(4-羟基-3,5-二甲基苯基)-6,8-二甲氧基异喹啉 -1(2H)-酮 | 活性 |
实施例 编号 | 化合物名称 | EC50 蛋白质 (μM) |
20 | 4-氯-N-(2-(4-(5,7-二甲氧基-4-氧代-3,4-二氢喹唑啉-2- 基)-2,6-二甲基苯氧基)乙基)苯磺酰胺 | 0.32 |
18 | 2-(4-(2-氨基乙氧基)-3,5-二甲基苯基)-5,7-二甲氧基喹 唑啉-4(3H)-酮 | 7.22 |
18 | N1-(2-(4-(5,7-二甲氧基-4-氧代-3,4-二氢喹唑啉-2- 基)-2,6-二甲基苯氧基)乙基)-N2-甲基邻苯二甲酰胺 | 7.29 |
17 | 2-(4-氨基-3,5-二甲基苯基)-5,7-二甲氧基喹唑啉 -4(3H)-酮 | 7.63 |
16 | 5,7-二甲氧基-2-(4-甲氧基-3,5-二甲基苯基)喹唑啉 -4(3H)-酮 | 16.46 |
15 | 2-(2-氯-6-甲基吡啶-4-基)-5,7-二甲氧基喹唑啉-4(3H)- 酮 | 3.96 |
14 | 2-(4-(2-羟基乙氧基)-3,5-二甲基苯基)-5,7-二甲氧基吡 啶并[2,3-d]嘧啶-4(3H)-酮 | 9.20 |
13 | 2-(4-((4-乙基哌嗪-1-基)甲基)苯基)-5,7-二甲氧基喹唑 啉-4(3H)-酮 | 13.72 |
实施例 编号 | 化合物名称 | EC50 蛋白质 (μM) |
12 | 2-(2,3-二氢苯并[b][1,4]二噁烯-6-基)-6,7-二甲氧基喹 唑啉-4(3H)-酮 | 9.07 |
11 | 2-(4-(双(2-羟基乙基)氨基)苯基)-6,7-二甲氧基喹唑啉 -4(3H)-酮 | 13.30 |
10 | 2-(4-(双(2-羟基乙基)氨基)苯基)-5,7-二甲氧基喹唑啉 -4(3H)-酮 | 12.11 |
9 | 2-(4-羟基-3-甲氧基苯基)-5,7-二甲氧基喹唑啉-4(3H)- 酮 | 12.08 |
8 | 3-(3,5-二甲基-4-(2-(4-甲基哌嗪-1-基)乙氧基)苯 基)-6,8-二甲氧基异喹啉-1(2H)-酮 | 2.82 |
7 | 2-(4-(2-羟基乙氧基)-3,5-二甲基苯基)-5,7-二甲氧基喹 唑啉-4(3H)-酮 | 12.16 |
6 | 7-(4-羟基-3,5-二甲基苯基)-2,4-二甲氧基-1,6-萘啶 -5(6H)-酮 | 6.52 |
5 | 3-(4-(2-羟基-2-甲基丙氧基)-3,5-二甲基苯基)-6,8-二甲 氧基异喹啉-1(2H)-酮 | 6.27 |
4 | 2-(4-羟基-3,5-二甲基苯基)-5,7-二甲氧基喹唑啉 -4(3H)-酮 | 7.93 |
3 | 3-(4-羟基-3,5-二甲基苯基)-7-(吗啉代基甲基)异喹啉 -1(2H)-酮 | 11.09 |
2 | 3-(4-(2-羟基乙氧基)-3,5-二甲基苯基)-6,8-二甲氧基异 喹啉-1(2H)-酮 | 11.35 |
1 | 3-(4-羟基-3,5-二甲基苯基)-6,8-二甲氧基异喹啉 -1(2H)-酮 | 5.42 |
2-(4-羟基-苯基)-吡喃并[2,3-b]吡啶-4-酮 | 179.47 |
Claims (11)
Priority Applications (1)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
CN201310229315.9A CN103319408B (zh) | 2007-02-01 | 2007-02-01 | 用于预防和治疗心血管疾病的化合物 |
Applications Claiming Priority (2)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
PCT/CA2007/000146 WO2008092231A1 (en) | 2007-02-01 | 2007-02-01 | Compounds for the prevention and treatment of cardiovascular diseases |
US11/670,238 US8053440B2 (en) | 2007-02-01 | 2007-02-01 | Compounds for the prevention and treatment of cardiovascular diseases |
Related Child Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
CN201310229315.9A Division CN103319408B (zh) | 2007-02-01 | 2007-02-01 | 用于预防和治疗心血管疾病的化合物 |
Publications (2)
Publication Number | Publication Date |
---|---|
CN101641339A CN101641339A (zh) | 2010-02-03 |
CN101641339B true CN101641339B (zh) | 2013-07-17 |
Family
ID=51894355
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
CN2007800523498A Active CN101641339B (zh) | 2007-02-01 | 2007-02-01 | 用于预防和治疗心血管疾病的化合物 |
Country Status (17)
Country | Link |
---|---|
US (7) | US8053440B2 (zh) |
EP (1) | EP2118074B1 (zh) |
JP (1) | JP5236664B2 (zh) |
KR (1) | KR101444489B1 (zh) |
CN (1) | CN101641339B (zh) |
AU (1) | AU2007345526B2 (zh) |
CA (1) | CA2676984C (zh) |
CY (1) | CY1115236T1 (zh) |
DK (1) | DK2118074T3 (zh) |
ES (1) | ES2454966T3 (zh) |
HK (1) | HK1136283A1 (zh) |
MX (1) | MX2009008099A (zh) |
NZ (1) | NZ579355A (zh) |
PL (1) | PL2118074T3 (zh) |
PT (1) | PT2118074E (zh) |
SI (1) | SI2118074T1 (zh) |
WO (1) | WO2008092231A1 (zh) |
Cited By (2)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US10111885B2 (en) | 2015-03-13 | 2018-10-30 | Resverlogix Corp. | Compositions and therapeutic methods for the treatment of complement-associated diseases |
US10131640B2 (en) | 2009-03-18 | 2018-11-20 | Resverlogix Corp. | Anti-inflammatory agents |
Families Citing this family (88)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US20040033480A1 (en) * | 2002-08-15 | 2004-02-19 | Wong Norman C.W. | Use of resveratrol to regulate expression of apolipoprotein A1 |
NZ566180A (en) * | 2005-07-29 | 2011-04-29 | Resverlogix Corp | Pharmaceutical compositions for the prevention and treatment of complex diseases and their delivery by insertable medical devices |
PT2118074E (pt) | 2007-02-01 | 2014-03-20 | Resverlogix Corp | Compostos para a prevenção e tratamento de doenças cardiovasculares |
US20080255161A1 (en) * | 2007-04-11 | 2008-10-16 | Dmitry Koltun | 3-HYDROQUINAZOLIN-4-ONE DERIVATIVES FOR USE AS STEAROYL CoA DESATURASE INHIBITORS |
BRPI0911259A2 (pt) * | 2008-04-15 | 2015-10-06 | Intermune Inc | composto, composição farmacêutica, método de inibição da atividade da polimerase de ns5b in vitro e usos de compostos |
PL2346837T3 (pl) * | 2008-06-26 | 2015-07-31 | Resverlogix Corp | Sposoby wytwarzania pochodnych chinazolinonu |
CN101628913B (zh) * | 2008-07-18 | 2013-01-23 | 中国科学院广州生物医药与健康研究院 | 用作雌激素相关受体调节剂的化合物及其应用 |
US8604049B2 (en) | 2008-08-05 | 2013-12-10 | Boehringer Ingelheim International Gmbh | 4-dimethylamino-phenyl-substituted naphthyridines, and use thereof as medicaments |
US20100267752A1 (en) * | 2008-10-15 | 2010-10-21 | Gilead Palo Alto, Inc. | 3-HYDROQUINAZOLIN-4-ONE DERIVATIVES FOR USE AS STEAROYL CoA DESATURASE INHIBITORS |
US8420668B2 (en) | 2008-11-28 | 2013-04-16 | Chugai Seiyaku Kabushiki Kaisha | 1-(2H)-isoquinolone derivative |
US8952021B2 (en) | 2009-01-08 | 2015-02-10 | Resverlogix Corp. | Compounds for the prevention and treatment of cardiovascular disease |
MX352614B (es) * | 2009-04-22 | 2017-12-01 | Resverlogix Corp | Nuevos agentes anti-inflamatorios. |
TW201121968A (en) * | 2009-11-09 | 2011-07-01 | Intermune Inc | Novel inhibitors of hepatitis C virus replication |
EP2528915B1 (en) * | 2010-01-29 | 2015-10-28 | Boehringer Ingelheim International GmbH | Substituted naphthyridines and their use as syk kinase inhibitors |
US8933024B2 (en) | 2010-06-18 | 2015-01-13 | Sanofi | Azolopyridin-3-one derivatives as inhibitors of lipases and phospholipases |
CA2804593C (en) | 2010-07-09 | 2015-11-24 | Pfizer Limited | Biphenyloxybenzensulphonamide derivatives useful as sodium channel inhibitors |
US9096500B2 (en) | 2010-07-12 | 2015-08-04 | Pfizer Limited | Acyl sulfonamide compounds |
CA2801032A1 (en) | 2010-07-12 | 2012-01-19 | Pfizer Limited | N-sulfonylbenzamide derivatives useful as voltage gated sodium channel inhibitors |
US9102621B2 (en) | 2010-07-12 | 2015-08-11 | Pfizer Limited | Acyl sulfonamide compounds |
US8772343B2 (en) | 2010-07-12 | 2014-07-08 | Pfizer Limited | Chemical compounds |
EP2593427B1 (en) | 2010-07-12 | 2014-12-24 | Pfizer Limited | Sulfonamide derivatives as nav1.7 inhibitors for the treatment of pain |
WO2012019093A1 (en) * | 2010-08-05 | 2012-02-09 | Human Biomolecular Research Institute | Synthetic compounds and methods to decrease nicotine self-administration |
JP5860960B2 (ja) | 2011-07-26 | 2016-02-16 | ベーリンガー インゲルハイム インターナショナル ゲゼルシャフト ミット ベシュレンクテル ハフツング | 置換キノリン類及び医薬としてのそれらの使用 |
WO2013033269A1 (en) | 2011-08-29 | 2013-03-07 | Coferon, Inc. | Bioorthogonal monomers capable of dimerizing and targeting bromodomains and methods of using same |
WO2013033268A2 (en) | 2011-08-29 | 2013-03-07 | Coferon, Inc. | Bivalent bromodomain ligands, and methods of using same |
EP2567959B1 (en) | 2011-09-12 | 2014-04-16 | Sanofi | 6-(4-hydroxy-phenyl)-3-styryl-1h-pyrazolo[3,4-b]pyridine-4-carboxylic acid amide derivatives as kinase inhibitors |
US8710064B2 (en) * | 2011-10-20 | 2014-04-29 | China Medical University | 2-aryl-4-quinazolinones and their pharmaceutical compositions |
PT2773354T (pt) | 2011-11-01 | 2019-07-17 | Resverlogix Corp | Formulações orais de libertação imediata para quinazolinonas substituídas |
CN102516169B (zh) * | 2011-12-31 | 2014-05-28 | 清华大学 | 制备多取代异喹啉及杂环并吡啶衍生物的方法 |
ES2611504T3 (es) | 2012-03-07 | 2017-05-09 | Institute Of Cancer Research: Royal Cancer Hospital (The) | Compuestos de isoquinolin-1-ona 3-aril-5-sustituida y sus usos terapéuticos |
PL2882714T3 (pl) | 2012-08-08 | 2020-02-28 | Merck Patent Gmbh | Pochodne (aza-)izochinolinonowe |
MX338885B (es) * | 2012-10-15 | 2016-05-04 | Resverlogix Corp | Compuestos utiles en la sintesis de compuestos de benzamida. |
JP6289479B2 (ja) * | 2012-10-15 | 2018-03-07 | アルベマール・コーポレーシヨン | 2−アミノ−4,6−ジメトキシベンズアミド及び他のベンズアミド化合物の合成方法 |
WO2014080291A2 (en) * | 2012-11-21 | 2014-05-30 | Rvx Therapeutics Inc. | Biaryl derivatives as bromodomain inhibitors |
US9073878B2 (en) | 2012-11-21 | 2015-07-07 | Zenith Epigenetics Corp. | Cyclic amines as bromodomain inhibitors |
US9271978B2 (en) | 2012-12-21 | 2016-03-01 | Zenith Epigenetics Corp. | Heterocyclic compounds as bromodomain inhibitors |
WO2014164596A1 (en) | 2013-03-11 | 2014-10-09 | The Regents Of The University Of Michigan | Bet bromodomain inhibitors and therapeutic methods using the same |
ES2661437T3 (es) | 2013-06-21 | 2018-04-02 | Zenith Epigenetics Corp. | Nuevos compuestos bicíclicos sustituidos como inhibidores de bromodominio |
MX365864B (es) | 2013-06-21 | 2019-06-18 | Zenith Epigenetics Ltd | Inhibidores de bromodominio biciclicos novedosos. |
CN105593224B (zh) | 2013-07-31 | 2021-05-25 | 恒元生物医药科技(苏州)有限公司 | 作为溴结构域抑制剂的新型喹唑啉酮类化合物 |
US20160206617A1 (en) * | 2013-08-21 | 2016-07-21 | Resverlogix Corp. | Compositions and therapeutic methods for accelerated plaque regression |
MX2016002178A (es) * | 2013-08-21 | 2016-06-06 | Resverlogix Corp | Composiciones y metodos terapeuticos para la regresion acelerada de placa. |
DK3044221T3 (en) | 2013-09-11 | 2018-04-23 | Institute Of Cancer Res Royal Cancer Hospital The | 3-ARYL-5-SUBSTITUTED-ISOQUINOLIN-1-ON COMPOUNDS AND THERAPEUTIC APPLICATION THEREOF |
JP6527513B2 (ja) * | 2013-11-20 | 2019-06-05 | シグナルケム・ライフサイエンシーズ・コーポレイションSignalchem Lifesciences Corporation | Tamファミリーキナーゼ阻害剤としてのキナゾリン誘導体 |
US9580430B2 (en) | 2014-02-28 | 2017-02-28 | The Regents Of The University Of Michigan | 9H-pyrimido[4,5-B]indoles and related analogs as BET bromodomain inhibitors |
RU2016144908A (ru) | 2014-05-02 | 2018-06-05 | Серени Терапеутикс Холдинг Са | Маркеры hdl-терапии |
US10179125B2 (en) | 2014-12-01 | 2019-01-15 | Zenith Epigenetics Ltd. | Substituted pyridines as bromodomain inhibitors |
EP3227281A4 (en) | 2014-12-01 | 2018-05-30 | Zenith Epigenetics Ltd. | Substituted pyridinones as bromodomain inhibitors |
CN107207474B (zh) | 2014-12-11 | 2021-05-07 | 恒翼生物医药科技(上海)有限公司 | 被取代的杂环作为溴结构域抑制剂 |
US10231953B2 (en) | 2014-12-17 | 2019-03-19 | Zenith Epigenetics Ltd. | Inhibitors of bromodomains |
WO2016138332A1 (en) | 2015-02-27 | 2016-09-01 | The Regents Of The University Of Michigan | 9h-pyrimido [4,5-b] indoles as bet bromodomain inhibitors |
WO2016196065A1 (en) | 2015-05-29 | 2016-12-08 | Genentech, Inc. | Methods and compositions for assessing responsiveness of cancers to bet inhibitors |
WO2017041701A1 (zh) * | 2015-09-07 | 2017-03-16 | 浙江华海药业股份有限公司 | 可释放一氧化氮的前药分子 |
AU2017219627B2 (en) | 2016-02-15 | 2021-08-05 | The Regents Of The University Of Michigan | Fused 1,4-oxazepines and related analogs as BET bromodomain inhibitors |
RU2021102253A (ru) | 2016-04-06 | 2021-03-03 | Дзе Риджентс Оф Дзе Юниверсити Оф Мичиган | Деструкторы белка mdm2 |
EP3440082A1 (en) | 2016-04-06 | 2019-02-13 | The Regents of The University of Michigan | Monofunctional intermediates for ligand-dependent target protein degradation |
AU2017250076B2 (en) | 2016-04-12 | 2021-07-22 | The Regents Of The University Of Michigan | Bet protein degraders |
JP6961684B2 (ja) | 2016-09-13 | 2021-11-05 | ザ リージェンツ オブ ザ ユニヴァシティ オブ ミシガン | Betタンパク質分解物質としての縮合1,4−オキサゼピン |
AU2017326175B2 (en) | 2016-09-13 | 2022-01-27 | The Regents Of The University Of Michigan | Fused 1,4-diazepines as BET protein degraders |
RU2016138751A (ru) * | 2016-09-30 | 2018-04-02 | Общество с ограниченной ответственностью "Диборнол Девелопмент" | Средство для лечения сердечно-сосудистых заболеваний |
JP6849804B2 (ja) * | 2016-12-09 | 2021-03-31 | クリスタル ファーマシューティカル(スーチョウ)カンパニー,リミテッド | ブロモドメインタンパク質阻害薬の結晶形及びその製造方法並びに用途 |
US11472776B2 (en) | 2016-12-20 | 2022-10-18 | Oligomerix, Inc. | Quinazolinones that inhibit the formation of tau oligomers and their method of use |
CA3047729A1 (en) | 2016-12-20 | 2018-06-28 | Oligomerix, Inc. | Novel benzofuran, benzothiophene, and indole analogs that inhibit the formation of tau oligomers and their method of use |
WO2018144789A1 (en) | 2017-02-03 | 2018-08-09 | The Regents Of The University Of Michigan | Fused 1,4-diazepines as bet bromodomain inhibitors |
CN108069954B (zh) * | 2017-03-03 | 2018-11-23 | 上海华汇拓医药科技有限公司 | 含no供体的喹唑啉酮化合物 |
ES2681124B1 (es) * | 2017-03-08 | 2019-06-19 | Fund Imdea Alimentacion | Usos medicos de la apolipoproteina a y de activadores de la misma |
CN109384784B (zh) * | 2017-08-10 | 2021-01-12 | 浙江海正药业股份有限公司 | 磺酰胺类衍生物、其制备方法及其在医药上的用途 |
US11267822B2 (en) | 2017-09-13 | 2022-03-08 | The Regents Of The University Of Michigan | BET bromodomain protein degraders with cleavable linkers |
CN108484510B (zh) * | 2018-05-18 | 2020-05-05 | 东南大学 | 一种基于brd4抑制剂rvx-208的衍生物及其制备方法和应用 |
KR20210020889A (ko) | 2018-06-13 | 2021-02-24 | 디블라이 아게 | 응축된 트리아제핀 유도체의 제조 및 이의 bet 억제제로서 용도 |
CN113453760A (zh) | 2018-12-17 | 2021-09-28 | 弗特克斯药品有限公司 | Apol1抑制剂及其使用方法 |
CN109776413A (zh) * | 2019-01-29 | 2019-05-21 | 天津科技大学 | 一种具有降糖活性的异喹啉衍生物和应用 |
CN109897009B (zh) * | 2019-03-15 | 2022-06-28 | 深圳晶泰科技有限公司 | 一种Apabetalone水合物晶型及其制备方法 |
CN109824608B (zh) * | 2019-03-15 | 2022-06-21 | 深圳晶泰科技有限公司 | 一种Apabetalone晶型及其制备方法 |
KR102420263B1 (ko) * | 2019-11-26 | 2022-07-13 | 주식회사 베노바이오 | 신규한 퀴나졸린 리독스 유도체 및 bet 억제제로서의 용도 |
CN114981263A (zh) * | 2019-11-26 | 2022-08-30 | 贝诺生物有限公司 | 新型槲皮素氧化还原衍生物及作为bet抑制剂的用途 |
KR20220124736A (ko) * | 2020-01-08 | 2022-09-14 | 리스버로직스 코퍼레이션 | Bet 브로모도메인 억제제 및 디펩티딜 펩티다아제 4 억제제의 조합을 이용해 주요 심혈관 이상 반응(mace)을 치료 및/또는 예방하는 방법 |
TW202139996A (zh) | 2020-03-06 | 2021-11-01 | 美商維泰克斯製藥公司 | 治療apol-1依賴性局灶性節段性腎小球硬化之方法 |
US11753413B2 (en) | 2020-06-19 | 2023-09-12 | Incyte Corporation | Substituted pyrrolo[2,1-f][1,2,4]triazine compounds as JAK2 V617F inhibitors |
WO2021257857A1 (en) | 2020-06-19 | 2021-12-23 | Incyte Corporation | Naphthyridinone compounds as jak2 v617f inhibitors |
US11767323B2 (en) | 2020-07-02 | 2023-09-26 | Incyte Corporation | Tricyclic pyridone compounds as JAK2 V617F inhibitors |
MX2023000056A (es) | 2020-07-02 | 2023-04-12 | Incyte Corp | Compuestos tricíclicos de urea como inhibidores de la variante v617f de la cinasa de janus 2 (jak2 v617f). |
KR20230057386A (ko) | 2020-08-26 | 2023-04-28 | 버텍스 파마슈티칼스 인코포레이티드 | Apol1 억제제 및 사용 방법 |
US11661422B2 (en) | 2020-08-27 | 2023-05-30 | Incyte Corporation | Tricyclic urea compounds as JAK2 V617F inhibitors |
US11919908B2 (en) | 2020-12-21 | 2024-03-05 | Incyte Corporation | Substituted pyrrolo[2,3-d]pyrimidine compounds as JAK2 V617F inhibitors |
EP4298099A1 (en) | 2021-02-25 | 2024-01-03 | Incyte Corporation | Spirocyclic lactams as jak2 v617f inhibitors |
CN115710202A (zh) * | 2021-08-23 | 2023-02-24 | 江西同和药业股份有限公司 | 一种阿帕他酮关键中间体的制备方法及其应用 |
TW202334089A (zh) | 2021-11-02 | 2023-09-01 | 美商夫雷爾醫療公司 | Pparg反向激動劑及其用途 |
Citations (1)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
EP0210342A2 (de) * | 1985-05-03 | 1987-02-04 | Dr. Karl Thomae GmbH | Arzneimittel, enthaltend Pyridinone mit antithrombotischer Wirkung |
Family Cites Families (286)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US4608A (en) * | 1846-06-27 | Netting-machine | ||
US4448A (en) * | 1846-04-04 | Xjoel | ||
US2065593A (en) * | 1936-12-29 | Water-soluble diazoimino com | ||
FR472489A (fr) | 1914-02-20 | 1914-12-08 | Stas Motor Ges M B H | Bague de garniture métallique pour pistons |
FR803619A (fr) | 1935-03-23 | 1936-10-05 | Ig Farbenindustrie Ag | Acide du type dihydroxystilbène-dicarboxylique et son procédé de préparation |
US2065900A (en) * | 1935-03-23 | 1936-12-29 | Gen Aniline Works Inc | Dihydroxystilbene-dicarboxylic acid and a process of preparing it |
DE637259C (de) | 1935-03-24 | 1936-10-27 | I G Farbenindustrie Akt Ges | Verfahren zur Darstellung einer Dioxystilbendicarbonsaeure |
FR803201A (fr) | 1935-07-08 | 1936-09-25 | Ste Ind Chim Bale | Préparation d'acides sulfoniques |
US2071329A (en) * | 1935-08-22 | 1937-02-23 | Solvay Process Co | Method of recovering phthalic anhydride |
DE652772C (de) | 1935-11-07 | 1937-11-08 | I G Farbenindustrie Akt Ges | Verfahren zur Herstellung von N-Dihydroazinen der Anthrachinonreihe |
GB728767A (en) | 1951-10-12 | 1955-04-27 | Wander Ag Dr A | 2-substituted chromone compounds, and a method of making same |
BE633049A (zh) | 1962-06-06 | |||
US3251837A (en) * | 1962-09-14 | 1966-05-17 | Pfizer & Co C | Derivatives of 1, 2, 4-benzothiadiazine-1, 1-dioxides |
GB1179019A (en) | 1967-05-23 | 1970-01-28 | Produits Chimique Soc Et | Polynicotinic Esters of Flavonoids |
FR6928M (zh) | 1967-11-24 | 1969-05-05 | ||
US3600394A (en) * | 1968-05-17 | 1971-08-17 | Searle & Co | 2-aminoalkyl-3-arylisocarbostyrils |
US3930024A (en) * | 1969-09-02 | 1975-12-30 | Parke Davis & Co | Pharmaceutical compositions and methods |
US3773946A (en) * | 1969-09-02 | 1973-11-20 | Parke Davis & Co | Triglyceride-lowering compositions and methods |
US3862186A (en) | 1972-12-15 | 1975-01-21 | Bristol Myers Co | Process for the production of cephalexin monohydrate |
FR2244493A1 (en) | 1973-08-09 | 1975-04-18 | Pluripharm | Flavonoid amino-acid salts - for treatment of haemorrhage, circulatory disorders and atherosclerosis |
DE2349024A1 (de) * | 1973-09-26 | 1975-04-10 | Schering Ag | 6beta,7beta-epoxy-1alpha,2alphamethylen-d-homo-4-pregnen-3,20-dione |
IT1050750B (it) | 1975-12-05 | 1981-03-20 | Erba Carlo Spa | Derivati della 3.4 di idro chinazolina |
GB1532682A (en) | 1976-04-27 | 1978-11-22 | Bristol Myers Co | Process for the preparation of cephadroxil |
US4159330A (en) | 1976-11-02 | 1979-06-26 | Carlo Erba S.P.A. | 2-Disubstituted phenyl-3,4-dihydro-4-oxo-quinazoline derivatives and process for their preparation |
US5098903A (en) | 1980-03-07 | 1992-03-24 | Board Of Regents Of The University Of Oklahoma | Diphenylcyclopropyl analogs as antiestrogenic and antitumor agents |
IL64542A0 (en) * | 1981-12-15 | 1982-03-31 | Yissum Res Dev Co | Long-chain alpha,omega-dicarboxylic acids and derivatives thereof and pharmaceutical compositions containing them |
JPS60136512A (ja) * | 1983-12-26 | 1985-07-20 | Eisai Co Ltd | 脂質代謝改善剤 |
DE3423166A1 (de) * | 1984-06-22 | 1986-01-02 | Epis S.A., Zug | Alpha-, omega-dicarbonsaeuren, verfahren zu ihrer herstellung und arzneimittel, die diese verbindungen enthalten |
EP0182213B1 (en) | 1984-11-08 | 1990-09-26 | Sumitomo Pharmaceuticals Company, Limited | Carbapenem compounds and production thereof |
DE3532279A1 (de) | 1985-09-11 | 1987-03-12 | Bayer Ag | 1,4-benzoxathiin-derivate |
ES2058061T3 (es) | 1985-10-25 | 1994-11-01 | Beecham Group Plc | Derivado de piperidina, su preparacion y su uso como medicamento. |
DE3601417A1 (de) | 1986-01-20 | 1987-07-23 | Nattermann A & Cie | 2'-alkyl-(alkenyl-) substituierte quercetine |
US4663345A (en) | 1986-04-17 | 1987-05-05 | American Home Products Corporation | Etodolac for treatment of gout |
EP0258190B1 (de) | 1986-08-29 | 1991-11-27 | Ciba-Geigy Ag | Verfahren zur Herstellung von aromatischen Ether- und Thioetherverbindungen |
ES2053508T3 (es) | 1986-11-24 | 1994-08-01 | Fujisawa Pharmaceutical Co | Compuestos de acidos 3-pirrolidinil-tio-1-azabiciclo(3.2.0)hept-2-eno-2-carboxilicos. |
JPH07118241B2 (ja) | 1987-10-21 | 1995-12-18 | 松下電器産業株式会社 | 器具の蓋開閉装置 |
GB8804058D0 (en) | 1988-02-22 | 1988-03-23 | Fujisawa Pharmaceutical Co | 3-alkenyl-1-azabicyclo(3 2 0)hept-2-ene-2-carboxylic acid compounds |
US4925838A (en) | 1988-03-18 | 1990-05-15 | Fujisawa Pharmaceutical Company, Ltd. | 3-pyrrolidinylthio-1-azabicyclo[3.2.0]-hept-2-ene-2-carboxylic acid compounds |
US4963544A (en) | 1988-05-23 | 1990-10-16 | Fujisawa Pharmaceutical Company, Ltd. | 3-pyrrolidinylthio-1-azabicyclo[3.2.0]-hept-2-ene-2-carboxylic acid compounds |
GB8926981D0 (en) | 1988-12-23 | 1990-01-17 | Ici Plc | Heterocyclic derivatives |
JPH0741442Y2 (ja) | 1989-01-31 | 1995-09-27 | シャープ株式会社 | 生体用電極保持体 |
EP0407217A1 (en) | 1989-07-07 | 1991-01-09 | Schering Corporation | Pharmaceutically active compounds |
FR2649612A1 (fr) | 1989-07-17 | 1991-01-18 | Rhone Poulenc Sante | Medicaments a base de derives de 1h-benzoxadiazine-4,1,2 nouveaux derives et leurs procedes de preparation |
IE64358B1 (en) | 1989-07-18 | 1995-07-26 | Ici Plc | Diaryl ether heterocycles |
US5332832A (en) | 1989-07-26 | 1994-07-26 | Procter & Gamble Pharmaceuticals, Inc. | Nitrofurantoin crystals |
GB9018134D0 (en) | 1989-09-29 | 1990-10-03 | Ici Plc | Heterocyclic derivatives |
EP0735026A1 (en) * | 1990-06-05 | 1996-10-02 | Toray Industries, Inc. | Method for the production of isoquinoline derivatives and their use as intermediates in the preparation of indole derivatives |
JP2999579B2 (ja) * | 1990-07-18 | 2000-01-17 | 武田薬品工業株式会社 | Dnaおよびその用途 |
IE913866A1 (en) | 1990-11-28 | 1992-06-03 | Ici Plc | Aryl derivatives |
GB9025832D0 (en) | 1990-11-28 | 1991-01-09 | Ashwell Geoffrey J | Novel films for nonlinear optical applications |
US5126351A (en) * | 1991-01-24 | 1992-06-30 | Glaxo Inc. | Antitumor compounds |
MX9200299A (es) | 1991-02-07 | 1992-12-01 | Roussel Uclaf | Nuevos derivados biciclicos nitrogenados, su procedimiento de preparacion los nuevos compuestos intermedios obtenidos su aplicacion como medicamentos y las composiciones farmaceuticas que los contienen. |
WO1992018123A2 (en) | 1991-04-10 | 1992-10-29 | Octamer, Inc. | A method for inhibition of retroviral replication |
US5480883A (en) * | 1991-05-10 | 1996-01-02 | Rhone-Poulenc Rorer Pharmaceuticals Inc. | Bis mono- and bicyclic aryl and heteroaryl compounds which inhibit EGF and/or PDGF receptor tyrosine kinase |
DE69222637T2 (de) | 1991-05-10 | 1998-02-26 | Rhone Poulenc Rorer Int | Bis mono- und bicyclische aryl- und heteroarylderivate mit inhibierender wirkung auf die egf und/oder pdgf-rezeptor tyrosinkinase |
US5124337A (en) * | 1991-05-20 | 1992-06-23 | Schering Corporation | N-acyl-tetrahydroisoquinolines as inhibitors of acyl-coenzyme a:cholesterol acyl transferase |
US5223506A (en) | 1991-06-04 | 1993-06-29 | Glaxo Inc. | Cyclic antitumor compounds |
PT100905A (pt) * | 1991-09-30 | 1994-02-28 | Eisai Co Ltd | Compostos heterociclicos azotados biciclicos contendo aneis de benzeno, ciclo-hexano ou piridina e de pirimidina, piridina ou imidazol substituidos e composicoes farmaceuticas que os contem |
US5250679A (en) | 1991-10-18 | 1993-10-05 | Genentech, Inc. | Nonpeptidyl platelet aggregation inhibitors having specificity for the GPIIb III.sub. receptor |
GB9126260D0 (en) | 1991-12-11 | 1992-02-12 | Pfizer Ltd | Therapeutic agents |
US5474994A (en) | 1992-05-26 | 1995-12-12 | Recordati S.A., Chemical And Pharmaceutical Company | Bicyclic heterocyclic derivatives having α1 -adrenergic and 5HT1A |
FR2689127B1 (fr) | 1992-03-31 | 1994-05-06 | Adir Cie | Nouvelles 3', 5' -ditertbutyl-4'-hydroxy flavones, leur procede de preparation et les compositions pharmaceutiques les renfermant. |
US7655699B1 (en) | 1992-04-22 | 2010-02-02 | Eisai Inc. | Compounds having selective activity for retinoid X receptors, and means for modulation of processes mediated by retinoid X receptors |
DE4215587A1 (de) * | 1992-05-12 | 1993-11-18 | Bayer Ag | Sulfonylbenzyl-substituierte Benzo- und Pyridopyridone |
DE4215588A1 (de) | 1992-05-12 | 1993-11-18 | Bayer Ag | Biphenylmethyl-substituierte Pyridone |
GB9218334D0 (en) | 1992-08-28 | 1992-10-14 | Ici Plc | Heterocyclic compounds |
JPH0680656A (ja) | 1992-09-03 | 1994-03-22 | Mitsui Petrochem Ind Ltd | 光学活性エポキシドの製造方法 |
WO1994014763A1 (en) | 1992-12-23 | 1994-07-07 | Procept, Inc. | Novel agents for inhibition of hiv infectivity and use therefor |
JPH0741442A (ja) | 1993-05-21 | 1995-02-10 | Sumitomo Chem Co Ltd | アセチレンアルコール誘導体およびその製造法 |
JPH0761942A (ja) | 1993-06-17 | 1995-03-07 | Sumitomo Chem Co Ltd | フェノール誘導体およびその製造法 |
JPH0725761A (ja) | 1993-07-09 | 1995-01-27 | Kureha Chem Ind Co Ltd | 軟骨保護剤 |
DE69428703T2 (de) * | 1993-07-23 | 2002-05-29 | Zaidan Hojin Biseibutsu | Pyrrolidin derivate |
US5707547A (en) | 1993-08-03 | 1998-01-13 | Sumitomo Chemical Company, Limited | Trans-olefin compounds, method for production thereof, liquid crystal composition containing the same as active ingredient, and liquid crystal element using said composition |
JPH07118241A (ja) | 1993-09-01 | 1995-05-09 | Sumitomo Chem Co Ltd | フェノール誘導体およびその製造法 |
JPH07179380A (ja) | 1993-12-22 | 1995-07-18 | Sumitomo Chem Co Ltd | アルコール誘導体およびその製造法 |
JPH07233109A (ja) | 1994-02-24 | 1995-09-05 | Sumitomo Chem Co Ltd | 光学活性なアルコール誘導体およびその製造法 |
AU680736B2 (en) | 1994-02-25 | 1997-08-07 | Banyu Pharmaceutical Co., Ltd. | Carbapenem derivative |
WO1995024410A1 (fr) * | 1994-03-08 | 1995-09-14 | Otsuka Pharmaceutical Factory, Inc. | Derive de diester phosphonique |
JPH07247289A (ja) | 1994-03-11 | 1995-09-26 | Mitsui Petrochem Ind Ltd | クロメンオキシド類の製造方法 |
FR2718329B1 (fr) * | 1994-03-21 | 2002-09-20 | Rhone Poulenc Rorer Sa | Lapin transgénique sensibilisé aux dyslipoprotéinémies. |
US6048903A (en) * | 1994-05-03 | 2000-04-11 | Robert Toppo | Treatment for blood cholesterol with trans-resveratrol |
US6168776B1 (en) * | 1994-07-19 | 2001-01-02 | University Of Pittsburgh | Alkyl, alkenyl and alkynyl Chrysamine G derivatives for the antemortem diagnosis of Alzheimer's disease and in vivo imaging and prevention of amyloid deposition |
GB2292149A (en) | 1994-08-09 | 1996-02-14 | Ferring Res Ltd | Peptide inhibitors of pro-interleukin-1beta converting enzyme |
JP3702493B2 (ja) | 1994-08-12 | 2005-10-05 | 大正製薬株式会社 | キナゾリン−4(3h)−オン誘導体 |
PT790997E (pt) | 1994-11-14 | 2000-06-30 | Warner Lambert Co | 6-aril pirido¬2,3-d|pirimidinas e naftiridinas para inibir a proliferacao celular mediada pela quinase da tirosina proteica |
IL115256A0 (en) * | 1994-11-14 | 1995-12-31 | Warner Lambert Co | 6-Aryl pyrido (2,3-d) pyrimidines and naphthyridines and their use |
US5446071A (en) * | 1994-11-18 | 1995-08-29 | Eli Lilly And Company | Methods for lowering serum cholesterol |
JP4140981B2 (ja) * | 1994-12-26 | 2008-08-27 | 東菱薬品工業株式会社 | 再狭窄症及び動脈硬化症治療薬 |
US5648387A (en) * | 1995-03-24 | 1997-07-15 | Warner-Lambert Company | Carboxyalkylethers, formulations, and treatment of vascular diseases |
WO1996031206A2 (en) | 1995-04-07 | 1996-10-10 | Warner-Lambert Company | Flavones and coumarins as agents for the treatment of atherosclerosis |
DE69622472T2 (de) | 1995-06-07 | 2003-02-06 | Lilly Co Eli | Behandlung von Krankheiten durch Induktion von BEF-1 Transkriptionsfaktor |
WO1997008153A1 (fr) * | 1995-08-30 | 1997-03-06 | Otsuka Pharmaceutical Factory, Inc. | Procede de production de derives de quinazolin-4-one |
US5783577A (en) | 1995-09-15 | 1998-07-21 | Trega Biosciences, Inc. | Synthesis of quinazolinone libraries and derivatives thereof |
AU4858596A (en) | 1995-09-15 | 1997-04-01 | Torrey Pines Institute For Molecular Studies | Synthesis of quinazolinone libraries |
AU706262B2 (en) | 1995-10-23 | 1999-06-10 | Osteoscreen, Inc. | Compositions and methods for treating bone deficit conditions |
RU2135494C1 (ru) | 1995-12-01 | 1999-08-27 | Санкио Компани Лимитед | Гетероциклические соединения и композиция на их основе, проявляющая антагонистическое действие в отношении рецепторов тахикинина |
US5756736A (en) * | 1996-01-26 | 1998-05-26 | Syntex (U.S.A.) Inc. | Process for preparing a 2-(2-amino-1,6-dihydro-6-oxo-purin-9-yl)methoxy-1,3-propanediol derivative |
US5763608A (en) | 1996-02-05 | 1998-06-09 | Hoechst Celanese Corporation | Process for preparing pyrimidine derivatives |
WO1997028118A1 (en) | 1996-02-05 | 1997-08-07 | Hoechst Celanese Corporation | Process for preparing anthranilic acids |
US5739330A (en) | 1996-02-05 | 1998-04-14 | Hoechst Celanese Corporation | Process for preparing quinazolones |
TR199801555T2 (xx) | 1996-02-12 | 1998-11-23 | Rutgers, The State University Of New Jersey | Topoizomeraz inhibit�rleri olarak koralin analoglar�. |
IL127559A0 (en) | 1996-06-20 | 1999-10-28 | Univ Texas | Compounds and methods for providing pharmacologically active preparations and uses thereof |
US5854264A (en) * | 1996-07-24 | 1998-12-29 | Merck & Co., Inc. | Inhibitors of farnesyl-protein transferase |
KR100213895B1 (ko) * | 1996-10-14 | 1999-08-02 | 박원훈 | 감귤류 과피 추출물, 이로부터 분리 정제된 헤스페리딘 또는 나린진을 포함하는 심혈관 질환 예방및 치료제 조성물 |
DE19651099A1 (de) | 1996-12-09 | 1998-06-10 | Consortium Elektrochem Ind | Mehrkomponentensystem zum Verändern, Abbau oder Bleichen von Lignin, ligninhaltigen Materialien oder ähnlichen Stoffen sowie Verfahren zu seiner Anwendung |
IL119971A (en) | 1997-01-07 | 2003-02-12 | Yissum Res Dev Co | Pharmaceutical compositions containing dicarboxylic acids and derivatives thereof and some novel dicarboxylic acids |
US6613722B1 (en) | 1997-03-07 | 2003-09-02 | Exxon Chemical Patents Inc. | Lubricating composition |
JPH10287678A (ja) | 1997-04-11 | 1998-10-27 | Kyowa Hakko Kogyo Co Ltd | ピラノアジン誘導体 |
AR012634A1 (es) | 1997-05-02 | 2000-11-08 | Sugen Inc | Compuesto basado en quinazolina, composicion famaceutica que lo comprende, metodo para sintetizarlo, su uso, metodos de modulacion de la funcion deserina/treonina proteinaquinasa con dicho compuesto y metodo in vitro para identificar compuestos que modulan dicha funcion |
US5908861A (en) * | 1997-05-13 | 1999-06-01 | Octamer, Inc. | Methods for treating inflammation and inflammatory disease using pADPRT inhibitors |
BR9809115A (pt) | 1997-05-13 | 2002-01-02 | Octamer Inc | Métodos para tratar inflamação e doenças inflamatórias usando inibidores de padprt |
KR100517832B1 (ko) | 1997-06-02 | 2005-09-30 | 얀센 파마슈티카 엔.브이. | 평활근 세포 증식 억제제로서의(이미다졸-5-일)메틸-2-퀴놀리논 유도체 |
IL121165A0 (en) | 1997-06-26 | 1997-11-20 | Yissum Res Dev Co | Pharmaceutical compositions containing carboxylic acids and derivatives thereof |
WO1999011634A1 (en) | 1997-08-29 | 1999-03-11 | Takeda Chemical Industries, Ltd. | Triazine derivatives, their production and use |
US20020022636A1 (en) | 1997-09-03 | 2002-02-21 | Jia-He Li | Oxo-substituted compounds, process of making, and compositions and methods for inhibiting parp activity |
US6635642B1 (en) * | 1997-09-03 | 2003-10-21 | Guilford Pharmaceuticals Inc. | PARP inhibitors, pharmaceutical compositions comprising same, and methods of using same |
US6239114B1 (en) * | 1997-09-26 | 2001-05-29 | Kgk Synergize | Compositions and methods for treatment of neoplastic diseases with combinations of limonoids, flavonoids and tocotrienols |
ATE404539T1 (de) | 1997-10-02 | 2008-08-15 | Eisai R&D Man Co Ltd | Kondensierte pyridinderivate |
CN1124134C (zh) * | 1997-10-28 | 2003-10-15 | 韩国科学技术研究院 | 柚苷和柚苷配基作为肝病的预防或治疗剂的应用 |
GB9725782D0 (en) | 1997-12-05 | 1998-02-04 | Pfizer Ltd | Therapeutic agents |
DE19756388A1 (de) * | 1997-12-18 | 1999-06-24 | Hoechst Marion Roussel De Gmbh | Substituierte 2-Aryl-4-amino-chinazoline |
DK1049767T3 (da) * | 1998-01-08 | 2005-09-19 | Aventis Pharma Inc | En transgen kanin, der udtrykker et funktionelt humant lipoprotein(A) |
US6414037B1 (en) * | 1998-01-09 | 2002-07-02 | Pharmascience | Pharmaceutical formulations of resveratrol and methods of use thereof |
PT1074268E (pt) | 1998-03-17 | 2008-02-28 | Chugai Pharmaceutical Co Ltd | Agentes profilácticos ou terapêuticos para doenças intestinais inflamatórias contendo anticorpos antagonistas do receptor il-6 |
US6022901A (en) * | 1998-05-13 | 2000-02-08 | Pharmascience Inc. | Administration of resveratrol to prevent or treat restenosis following coronary intervention |
SE9802973D0 (sv) | 1998-09-03 | 1998-09-03 | Astra Ab | Immediate release tablet |
KR20010079922A (ko) | 1998-09-24 | 2001-08-22 | 미우라 아키라 | 하이드록시플라본 유도체 |
KR20010103583A (ko) | 1998-10-19 | 2001-11-23 | 다니구치 미즈오 | 진통제 |
WO2000023073A1 (en) * | 1998-10-20 | 2000-04-27 | Korea Institute Of Science And Technology | Bioflavonoids as plasma high density lipoprotein level increasing agent |
US6433187B1 (en) | 1998-12-17 | 2002-08-13 | Tularik Inc. | Certain polycyclic compounds useful as tubulin-binding agents |
US6291456B1 (en) * | 1998-12-30 | 2001-09-18 | Signal Pharmaceuticals, Inc. | Compounds and methods for modulation of estrogen receptors |
US6399633B1 (en) | 1999-02-01 | 2002-06-04 | Aventis Pharmaceuticals Inc. | Use of 4-H-1-benzopryan-4-one derivatives as inhibitors of smooth muscle cell proliferation |
EP1161438B1 (en) | 1999-03-15 | 2004-05-06 | Abbott Laboratories | 6-o-substituted macrolides having antibacterial activity |
US6969720B2 (en) * | 1999-03-17 | 2005-11-29 | Amr Technology, Inc. | Biaryl substituted purine derivatives as potent antiproliferative agents |
US6054435A (en) * | 1999-03-19 | 2000-04-25 | Abbott Laboratories | 6-O-substituted macrolides having antibacterial activity |
EP1177187B1 (en) | 1999-04-28 | 2007-07-25 | Sanofi-Aventis Deutschland GmbH | Di-aryl acid derivatives as ppar receptor ligands |
US6835755B1 (en) | 1999-06-24 | 2004-12-28 | University Of Pretoria | Naphthoquinone derivatives and their use in the treatment and control of tuberculosis |
DE19934799B4 (de) * | 1999-07-28 | 2008-01-24 | Az Electronic Materials (Germany) Gmbh | Chiral-smektische Flüssigkristallmischung und ihre Verwendung in Aktivmatrix-Displays mit hohen Kontrastwerten |
JP2001131151A (ja) | 1999-11-02 | 2001-05-15 | Shionogi & Co Ltd | オレフィン誘導体の新規用途 |
JP5278983B2 (ja) | 1999-11-17 | 2013-09-04 | 塩野義製薬株式会社 | アミド化合物の新規用途 |
US20030171429A1 (en) * | 1999-12-06 | 2003-09-11 | Genhui Chen | Anti-inflammatory and psoriasis treatment and protein kinase inhibition by hydroxyltilbenes and novel stilbene derivatives and analogues |
FR2804679B1 (fr) | 2000-02-07 | 2002-04-26 | Clariant France Sa | Nouveaux composes phenoliques derives des dialcoxyethanals, leur procede de preparation et leur application |
ES2225475T3 (es) | 2000-02-17 | 2005-03-16 | Appleton Papers Inc. | Procedimiento para preparar alcoxi- o aroxietanos. |
CA2407593C (en) | 2000-04-27 | 2011-01-11 | Yamanouchi Pharmaceutical Co. Ltd. | Fused heteroaryl derivatives |
WO2001082916A2 (en) | 2000-05-03 | 2001-11-08 | Tularik Inc. | Combination therapeutic compositions and methods of use |
US6548694B2 (en) | 2000-05-23 | 2003-04-15 | Hoffman-La Roche Inc. | N-(4-carbamimidoyl-phenyl)-glycine derivatives |
JP2001335476A (ja) | 2000-05-29 | 2001-12-04 | Shionogi & Co Ltd | 三環化合物の新規用途 |
WO2003024441A1 (fr) | 2001-09-14 | 2003-03-27 | Shionogi & Co., Ltd. | Nouvelle utilisation de composes tricycliques |
US6479499B1 (en) | 2000-06-28 | 2002-11-12 | National Science Council | 2-phenyl-4-quinazolinone compounds, 2-phenyl-4-alkoxy-quinazoline compounds and their pharmaceutical compositions |
JP2002047283A (ja) | 2000-07-04 | 2002-02-12 | Basf Ag | 新規フラボノイドおよびそれらの化粧用または皮膚科用製品における使用 |
US6541522B2 (en) * | 2000-08-16 | 2003-04-01 | Insmed Incorporated | Methods of using compositions containing hypotriglyceridemically active stilbenoids |
US7723303B2 (en) | 2000-08-24 | 2010-05-25 | The Regents Of The University Of California | Peptides and peptide mimetics to treat pathologies characterized by an inflammatory response |
EP1322625A2 (en) | 2000-10-02 | 2003-07-02 | Molecular Probes Inc. | Reagents for labeling biomolecules having aldehyde or ketone moieties |
CA2356544C (en) | 2000-10-03 | 2006-04-04 | Warner-Lambert Company | Pyridotriazines and pyridopyridazines |
IL155196A0 (en) * | 2000-10-05 | 2003-11-23 | Fujisawa Pharmaceutical Co | Benzamide derivatives and pharmaceutical compositions containing the same |
MXPA03003022A (es) * | 2000-10-11 | 2003-07-14 | Esperion Therapeutics Inc | Compuestos de sulfuro y disulfuro y composiciones para el control del colesterol y usos relacionados. |
MXPA03003024A (es) * | 2000-10-11 | 2003-07-14 | Esperion Therapeutics Inc | Compuestos de sulfoxido y bis-sulfoxido y composiciones para el control de colesterol y usos relacionados. |
EP1333827A2 (en) | 2000-10-19 | 2003-08-13 | Merck & Co., Inc. | Estrogen receptor modulators |
KR100798562B1 (ko) * | 2000-11-30 | 2008-01-31 | 캐논 가부시끼가이샤 | 발광 소자 및 표시 장치 |
AU3950802A (en) * | 2000-12-07 | 2002-06-18 | Cv Therapeutics Inc | Abca-1 elevating compounds |
KR100472694B1 (ko) * | 2000-12-30 | 2005-03-07 | 한국생명공학연구원 | 플라바논 유도체 및 이를 포함하는 혈중 지질 농도 관련질환의 예방 및 치료용 조성물 |
JP2002249483A (ja) | 2001-02-21 | 2002-09-06 | Koei Chem Co Ltd | アリール置換複素環式化合物の製造法 |
JP4256679B2 (ja) | 2001-03-16 | 2009-04-22 | ノボゲン リサーチ ピーティーワイ リミテッド | 再狭窄の治療方法 |
JP4334233B2 (ja) * | 2001-04-11 | 2009-09-30 | アセロジエニクス・インコーポレイテツド | プロブコールモノエステルによって血漿hdlコレステロールレベルを上昇させ、hdlの機能性を改善するための方法 |
ATE445400T1 (de) | 2001-05-25 | 2009-10-15 | Bristol Myers Squibb Co | Hydantion-derivate als hemmer von matrix- metalloproteinasen |
WO2003007959A1 (en) | 2001-07-16 | 2003-01-30 | Fujisawa Pharmaceutical Co., Ltd. | Quinoxaline derivatives which have parp inhibitory action |
EP1430038A1 (en) * | 2001-08-13 | 2004-06-23 | Ciba SC Holding AG | Ultraviolet light absorbers |
EP1419770A4 (en) | 2001-08-24 | 2005-08-03 | Shionogi & Co | AGENT ACC L RATION OF THE EXPRESSION OF APO AI |
US7429593B2 (en) * | 2001-09-14 | 2008-09-30 | Shionogi & Co., Ltd. | Utilities of amide compounds |
US8124625B2 (en) * | 2001-09-14 | 2012-02-28 | Shionogi & Co., Ltd. | Method of enhancing the expression of apolipoprotein AI using olefin derivatives |
US6835469B2 (en) * | 2001-10-17 | 2004-12-28 | The University Of Southern California | Phosphorescent compounds and devices comprising the same |
US7166368B2 (en) | 2001-11-07 | 2007-01-23 | E. I. Du Pont De Nemours And Company | Electroluminescent platinum compounds and devices made with such compounds |
US7250512B2 (en) | 2001-11-07 | 2007-07-31 | E. I. Du Pont De Nemours And Company | Electroluminescent iridium compounds having red-orange or red emission and devices made with such compounds |
US6541045B1 (en) * | 2002-01-04 | 2003-04-01 | Nutraceutical Corporation | Herbal composition and method for combating inflammation |
JP4389204B2 (ja) | 2002-01-28 | 2009-12-24 | 宇部興産株式会社 | キナゾリン−4−オン誘導体の製造方法 |
US20040127492A1 (en) | 2002-02-19 | 2004-07-01 | Pharmacia Corporation | Cyclic pyrazoles for the inhibition of mitogen activated protein kinase-activated protein kinase-2 |
GB0206033D0 (en) | 2002-03-14 | 2002-04-24 | Pfizer Ltd | Compounds useful in therapy |
NZ556545A (en) | 2002-03-22 | 2009-03-31 | Novartis Ag | Combination comprising a beta-hydroxy-beta-methylglutaryl-co-enzyme-A reductase inhibitor and a glucagon-like peptide-1 agonist |
MY140680A (en) | 2002-05-20 | 2010-01-15 | Bristol Myers Squibb Co | Hepatitis c virus inhibitors |
WO2003106435A1 (en) * | 2002-06-18 | 2003-12-24 | Sankyo Company, Limited | Fused-ring pyrimidin-4(3h)-one derivatives, processes for the preparation and uses thereof |
KR20040001144A (ko) * | 2002-06-27 | 2004-01-07 | 김대경 | 신규한 적혈구 세포질형 포스포리파아제 에이 투 효소,그에 대한 항체, 이들의 용도 및 제조 방법 |
US20040033480A1 (en) * | 2002-08-15 | 2004-02-19 | Wong Norman C.W. | Use of resveratrol to regulate expression of apolipoprotein A1 |
US20050080021A1 (en) * | 2002-08-15 | 2005-04-14 | Joseph Tucker | Nitric oxide donating derivatives of stilbenes, polyphenols and flavonoids for the treatment of cardiovascular disorders |
US20050080024A1 (en) * | 2002-08-15 | 2005-04-14 | Joseph Tucker | Nitric oxide donating derivatives for the treatment of cardiovascular disorders |
EP1542948A4 (en) | 2002-08-23 | 2008-12-17 | Univ Connecticut | NEW BIPHENYL AND BIPHENYLENE CANNABINOIDS |
AU2003262946A1 (en) | 2002-08-30 | 2004-03-19 | Pharmacia And Upjohn Company | Method of preventing or treating atherosclerosis or restenosis |
EP1407774A1 (en) * | 2002-09-10 | 2004-04-14 | LION Bioscience AG | 2-Amino-4-quinazolinones as LXR nuclear receptor binding compounds |
EP1398032A1 (en) | 2002-09-10 | 2004-03-17 | PheneX Pharmaceuticals AG | 4-Oxo-quinazolines as LXR nuclear receptor binding compounds |
AU2003284001A1 (en) | 2002-10-07 | 2004-05-04 | Bristol-Myers Squibb Company | Triazolone and triazolethione derivatives |
US20040132732A1 (en) | 2002-10-21 | 2004-07-08 | Wei Han | Quinazolinones and derivatives thereof as factor Xa inhibitors |
WO2004039795A2 (en) | 2002-10-29 | 2004-05-13 | Fujisawa Pharmaceutical Co., Ltd. | Amide compounds for the treatment of hyperlipidemia |
CA2502302A1 (en) | 2002-11-04 | 2004-05-21 | Nps Pharmaceuticals, Inc. | Quinazolinone compounds as calcilytics |
EP1418164A1 (en) | 2002-11-07 | 2004-05-12 | Institut National De La Sante Et De La Recherche Medicale (Inserm) | New stilbene derivatives and their use as aryl hydrocarbon receptor ligand antagonists |
RU2340618C2 (ru) * | 2002-11-18 | 2008-12-10 | Ф.Хоффманн-Ля Рош Аг | Диазинопиримидины и фармацевтическая композиция, содержащая их |
NZ539952A (en) | 2002-11-22 | 2008-05-30 | Japan Tobacco Inc | Fused bicyclic nitrogen-containing heterocyclic compounds for treating diabetes, obesity and syndrome X |
ATE335729T1 (de) | 2002-12-13 | 2006-09-15 | Hoffmann La Roche | 3h-chinazoline -4-on derivaten |
ITRM20020629A1 (it) | 2002-12-19 | 2004-06-20 | Sigma Tau Ind Farmaceuti | Uso di acidi alfa-feniltiocarbossilici e alfa-fenilossicarbossilici ad attivita' ipoglicemizzante e/o ipolipidemizzante. |
AU2003301020A1 (en) * | 2002-12-20 | 2004-07-22 | Sankyo Company, Limited | Isoquinolinone derivatives and their use as therapeutic agents |
JP2004203751A (ja) | 2002-12-24 | 2004-07-22 | Pfizer Inc | 置換6,6−ヘテロ二環式誘導体 |
CA2512000C (en) * | 2002-12-26 | 2011-08-09 | Eisai Co., Ltd. | Selective estrogen receptor modulator |
WO2004065392A1 (en) | 2003-01-24 | 2004-08-05 | Smithkline Beecham Corporation | Condensed pyridines and pyrimidines and their use as alk-5 receptor ligands |
WO2004072042A2 (en) | 2003-02-12 | 2004-08-26 | Carex S.A. | Quinoline derivative and their use for modulation of lxr activity |
EP1615906A1 (en) * | 2003-04-03 | 2006-01-18 | Vertex Pharmaceuticals Incorporated | Compositions useful as inhibitors of protein kinases |
AU2004230928B2 (en) | 2003-04-09 | 2010-12-02 | Exelixis, Inc. | Tie-2 modulators and methods of use |
JP2004307440A (ja) | 2003-04-10 | 2004-11-04 | Kyorin Pharmaceut Co Ltd | 2−アミノ‐1,3‐プロパンジオール誘導体とその付加塩 |
ES2320771T3 (es) | 2003-04-16 | 2009-05-28 | Bristol-Myers Squibb Company | Inhibidores peptidicos de isoquinolina macrociclicos del virus de la hepatitis c. |
WO2004108139A2 (en) | 2003-06-06 | 2004-12-16 | Arexis Ab | Use of fused heterocyclic compounds as scce inhibitors for the treatment of skin conditions or cancer |
ES2389258T3 (es) | 2003-06-17 | 2012-10-24 | Millennium Pharmaceuticals, Inc. | Composiciones y métodos para inhibir TGF-s |
JP4631703B2 (ja) | 2003-06-18 | 2011-02-16 | 宇部興産株式会社 | ピリミジン−4−オン化合物の製造方法 |
US20050043300A1 (en) * | 2003-08-14 | 2005-02-24 | Pfizer Inc. | Piperazine derivatives |
CN1925862A (zh) | 2003-10-10 | 2007-03-07 | 雷斯弗洛吉克斯公司 | 与egr-1增强子元件有关的疾病的治疗 |
US20050096391A1 (en) | 2003-10-10 | 2005-05-05 | Per Holm | Compositions comprising fenofibrate and rosuvastatin |
WO2005042712A2 (en) | 2003-10-28 | 2005-05-12 | Reddy Us Therapeutics, Inc. | Heterocyclic compounds and methods of making and using thereof |
EP1696927A4 (en) | 2003-12-19 | 2007-10-31 | Merck & Co Inc | MITOTIC INHIBITORS OF KINESIN |
US20080188527A1 (en) | 2003-12-23 | 2008-08-07 | Cashman John R | Synthetic Compounds and Derivatives as Modulators of Smoking or Nicotine Ingestion and Lung Cancer |
TW200536830A (en) | 2004-02-06 | 2005-11-16 | Chugai Pharmaceutical Co Ltd | 1-(2H)-isoquinolone derivative |
AU2005247808B2 (en) * | 2004-05-31 | 2011-02-10 | Msd K.K. | Quinazoline derivative |
GB0512324D0 (en) | 2005-06-16 | 2005-07-27 | Novartis Ag | Organic compounds |
WO2006012577A2 (en) | 2004-07-22 | 2006-02-02 | Bayer Pharmaceuticals Corporation | Quinazolinone derivatives useful for the regulation of glucose homeostasis and food intake |
US20070218155A1 (en) * | 2004-08-20 | 2007-09-20 | Kuhrts Eric H | Methods and compositions for treating dyslipidaemia |
WO2006045096A2 (en) * | 2004-10-20 | 2006-04-27 | Resverlogix Corp. | Flavanoids and isoflavanoids for the prevention and treatment of cardiovascular diseases |
EP1844023A1 (en) | 2004-12-31 | 2007-10-17 | Sk Chemicals Co., Ltd. | Quinazoline derivatives for the treatment and prevention of diabetes and obesity |
CR9465A (es) | 2005-03-25 | 2008-06-19 | Surface Logix Inc | Compuestos mejorados farmacocineticamente |
NZ566180A (en) * | 2005-07-29 | 2011-04-29 | Resverlogix Corp | Pharmaceutical compositions for the prevention and treatment of complex diseases and their delivery by insertable medical devices |
EP1944301A4 (en) | 2005-10-27 | 2012-01-04 | Msd Kk | NEW BENZOXATHIIN DERIVATIVES |
EP1968968A1 (en) | 2005-12-21 | 2008-09-17 | PainCeptor Pharma Corp. | Compositions and methods for modulating gated ion channels |
US8835486B2 (en) | 2006-05-12 | 2014-09-16 | Evangelos Karavas | Pharmaceutical formulation containing an HMG-COA reductase inhibitor and method for the preparation thereof |
US20080085911A1 (en) | 2006-10-10 | 2008-04-10 | Reliant Pharmaceuticals, Inc. | Statin and omega-3 fatty acids for reduction of apo-b levels |
US20100249161A1 (en) | 2006-11-15 | 2010-09-30 | Anders Klarskov Petersen | 2- ( 2 -hydroxyphenyl) -quinazolin-4-ones useful for treating obesity and diabetes |
JP2010513458A (ja) | 2006-12-19 | 2010-04-30 | ファイザー・プロダクツ・インク | H−pgdsの阻害剤としてのニコチンアミド誘導体、およびプロスタグランジンd2の仲介による疾患を治療するためのその使用 |
PT2118074E (pt) | 2007-02-01 | 2014-03-20 | Resverlogix Corp | Compostos para a prevenção e tratamento de doenças cardiovasculares |
ES2308916B1 (es) | 2007-03-22 | 2009-10-29 | Consejo Superior De Investigaciones Cientificas | Compuesto inhibidor dual de las enzimas pde7 y/o pde4, composiciones farmaceuticas y sus aplicaciones. |
EP2005941A3 (de) | 2007-06-01 | 2009-04-01 | Henkel AG & Co. KGaA | Zellverjüngende Zusammensetzungen |
WO2008152471A1 (en) | 2007-06-12 | 2008-12-18 | Coley Pharmaceutical Group, Inc. | Quinazoline derivative useful as toll-like receptor antagonist |
WO2008157575A1 (en) | 2007-06-21 | 2008-12-24 | Irm Llc | Protein kinase inhibitors and methods for using thereof |
US8476260B2 (en) | 2007-12-28 | 2013-07-02 | Mitsubishi Tanabe Pharma Corporation | Antitumor agent |
PL2346837T3 (pl) | 2008-06-26 | 2015-07-31 | Resverlogix Corp | Sposoby wytwarzania pochodnych chinazolinonu |
EP2324022A1 (de) | 2008-08-05 | 2011-05-25 | Boehringer Ingelheim International GmbH | Substituierte naphthyridine und ihre verwendung als arzneimittel |
KR20110074898A (ko) | 2008-10-06 | 2011-07-04 | 카롤러스 테라퓨틱스, 인코포레이티드 | 염증을 치료하는 방법 |
BRPI0914406A2 (pt) | 2008-10-30 | 2015-10-20 | Circomed Llc | composto, composição farmacêutica, e, método para aumentar os níveis no plasma de apo a1 em um mamífero |
US20100183598A1 (en) | 2008-11-12 | 2010-07-22 | Carolus Therapeutics, Inc. | Methods of treating cardiovascular disorders |
US8952021B2 (en) | 2009-01-08 | 2015-02-10 | Resverlogix Corp. | Compounds for the prevention and treatment of cardiovascular disease |
TW201035083A (en) | 2009-03-06 | 2010-10-01 | Hoffmann La Roche | Heterocyclic antiviral compounds |
AU2010224523B2 (en) | 2009-03-18 | 2014-05-08 | Resverlogix Corp. | Novel anti-inflammatory agents |
MX352614B (es) | 2009-04-22 | 2017-12-01 | Resverlogix Corp | Nuevos agentes anti-inflamatorios. |
CA2759176C (en) | 2009-04-29 | 2016-03-15 | Amarin Corporation Plc | Pharmaceutical compositions comprising epa and a cardiovascular agent and methods of using the same |
ES2353093B1 (es) | 2009-05-20 | 2012-01-03 | Consejo Superior De Investigaciones Científicas (Csic) | Uso de derivados de quinazolinas y sus composiciones farmacéuticas en enfermedades neurodegenerativas. |
GB201007286D0 (en) | 2010-04-30 | 2010-06-16 | Astex Therapeutics Ltd | New compounds |
DE102010048800A1 (de) | 2010-10-20 | 2012-05-10 | Merck Patent Gmbh | Chinoxalinderivate |
GB201018147D0 (en) | 2010-10-27 | 2010-12-08 | Glaxo Group Ltd | Method of treatment |
AR084070A1 (es) | 2010-12-02 | 2013-04-17 | Constellation Pharmaceuticals Inc | Inhibidores del bromodominio y usos de los mismos |
EP2675445A1 (en) | 2011-02-16 | 2013-12-25 | Pivotal Therapeutics, Inc. | Statin and omega 3 fatty acids (epa, dha and dpa) for use in cardiovascular diseases |
WO2012174487A2 (en) | 2011-06-17 | 2012-12-20 | Constellation Pharmaceuticals, Inc. | Bromodomain inhibitors and uses thereof |
BR112014007781A2 (pt) | 2011-09-30 | 2017-04-11 | Kineta Inc | compostos anti-virais |
PT2773354T (pt) | 2011-11-01 | 2019-07-17 | Resverlogix Corp | Formulações orais de libertação imediata para quinazolinonas substituídas |
US20130281399A1 (en) | 2012-04-19 | 2013-10-24 | Rvx Therapeutics Inc. | Treatment of diseases by epigenetic regulation |
US20130281398A1 (en) | 2012-04-19 | 2013-10-24 | Rvx Therapeutics Inc. | Treatment of diseases by epigenetic regulation |
US20130281397A1 (en) | 2012-04-19 | 2013-10-24 | Rvx Therapeutics Inc. | Treatment of diseases by epigenetic regulation |
WO2013184878A1 (en) | 2012-06-06 | 2013-12-12 | Constellation Pharmaceuticals, Inc. | Benzo [b] isoxazoloazepine bromodomain inhibitors and uses thereof |
JP6289479B2 (ja) | 2012-10-15 | 2018-03-07 | アルベマール・コーポレーシヨン | 2−アミノ−4,6−ジメトキシベンズアミド及び他のベンズアミド化合物の合成方法 |
MX338885B (es) | 2012-10-15 | 2016-05-04 | Resverlogix Corp | Compuestos utiles en la sintesis de compuestos de benzamida. |
US9073878B2 (en) | 2012-11-21 | 2015-07-07 | Zenith Epigenetics Corp. | Cyclic amines as bromodomain inhibitors |
US9271978B2 (en) | 2012-12-21 | 2016-03-01 | Zenith Epigenetics Corp. | Heterocyclic compounds as bromodomain inhibitors |
CA2897448A1 (en) | 2013-01-08 | 2014-07-17 | Jerome Schentag | Activation of the endogenous ileal brake hormone pathway for organ regeneration and related compositions, methods of treatment, diagnostics, and regulatory systems |
EP2961411A4 (en) | 2013-02-28 | 2016-11-23 | Univ Washington | METHOD FOR TREATING INFECTIONS WITH HUMAN CYTOMAL GALOVIRUS AND DISEASES WITH BROMDOMAIN DISEASES |
WO2014164596A1 (en) | 2013-03-11 | 2014-10-09 | The Regents Of The University Of Michigan | Bet bromodomain inhibitors and therapeutic methods using the same |
MX367420B (es) | 2013-03-14 | 2019-08-21 | Convergene Llc | Metodos y composiciones para inhibicion de proteinas que contienen bromodominio. |
ES2685269T3 (es) | 2013-03-27 | 2018-10-08 | F. Hoffmann-La Roche Ag | Marcadores genéticos para predecir el grado de respuesta al tratamiento |
TWI530499B (zh) | 2013-03-28 | 2016-04-21 | 吉李德科學股份有限公司 | 作為溴結構域(bromodomain)抑制劑之苯並咪唑酮衍生物類 |
US20160206617A1 (en) | 2013-08-21 | 2016-07-21 | Resverlogix Corp. | Compositions and therapeutic methods for accelerated plaque regression |
MX2016002178A (es) | 2013-08-21 | 2016-06-06 | Resverlogix Corp | Composiciones y metodos terapeuticos para la regresion acelerada de placa. |
US9814728B2 (en) | 2013-09-20 | 2017-11-14 | Saint Louis University | Inhibition of DUX4 expression using bromodomain and extra-terminal domain protein inhibitors (BETi) |
US20170044127A1 (en) | 2014-01-23 | 2017-02-16 | H. Lee Moffitt Cancer Center And Research Institute, Inc. | Icariin derivatives |
IL300472A (en) | 2014-07-30 | 2023-04-01 | Hoffmann La Roche | Genetic markers for predicting reactivity to treatment with HDL-raising or HDL-lowering agents |
WO2016123054A2 (en) | 2015-01-26 | 2016-08-04 | The University Of North Carolina At Chapel Hill | Kinase drug combinations and methods of use thereof |
WO2016145294A1 (en) | 2015-03-12 | 2016-09-15 | The University Of Chicago | Methods for determining prognosis for breast cancer patients |
JO3789B1 (ar) | 2015-03-13 | 2021-01-31 | Resverlogix Corp | التراكيب والوسائل العلاجية المعتمدة لمعالجة الامراض المتعلقة بالمتممة |
CA2985203A1 (en) | 2015-05-08 | 2016-11-17 | President And Fellows Of Harvard College | Targeted selection of patients for treatment with cortistatin derivatives |
EP3307728A4 (en) | 2015-06-12 | 2019-07-17 | Dana Farber Cancer Institute, Inc. | ASSOCIATION THERAPY USING TRANSCRIPTION INHIBITORS AND KINASE INHIBITORS |
CN106265679A (zh) | 2015-06-28 | 2017-01-04 | 复旦大学 | 溴结构域蛋白抑制剂在制备抗hiv-1潜伏治疗药物中的用途 |
US20180200261A1 (en) | 2015-07-20 | 2018-07-19 | Mayo Foundation For Medical Education And Research | Methods and materials for treating cancer |
WO2017037567A1 (en) | 2015-09-03 | 2017-03-09 | Pfizer Inc. | Regulators of frataxin |
US9896663B2 (en) | 2016-03-11 | 2018-02-20 | Peter Maccallum Cancer Institute | Leukaemia stem cell line, its method of production and uses thereof |
WO2017192691A1 (en) | 2016-05-03 | 2017-11-09 | Biogen Ma Inc. | Cell culture containing bromodomain inhibitors |
CN106176753A (zh) | 2016-07-15 | 2016-12-07 | 南方医科大学 | Rvx‑208作为hiv‑1潜伏感染逆转剂的应用 |
JP6849804B2 (ja) | 2016-12-09 | 2021-03-31 | クリスタル ファーマシューティカル(スーチョウ)カンパニー,リミテッド | ブロモドメインタンパク質阻害薬の結晶形及びその製造方法並びに用途 |
-
2007
- 2007-02-01 PT PT77105971T patent/PT2118074E/pt unknown
- 2007-02-01 PL PL07710597T patent/PL2118074T3/pl unknown
- 2007-02-01 DK DK07710597.1T patent/DK2118074T3/en active
- 2007-02-01 ES ES07710597.1T patent/ES2454966T3/es active Active
- 2007-02-01 US US11/670,238 patent/US8053440B2/en active Active
- 2007-02-01 KR KR1020097017716A patent/KR101444489B1/ko active IP Right Grant
- 2007-02-01 CA CA2676984A patent/CA2676984C/en active Active
- 2007-02-01 AU AU2007345526A patent/AU2007345526B2/en active Active
- 2007-02-01 JP JP2009547497A patent/JP5236664B2/ja active Active
- 2007-02-01 WO PCT/CA2007/000146 patent/WO2008092231A1/en active Application Filing
- 2007-02-01 EP EP07710597.1A patent/EP2118074B1/en active Active
- 2007-02-01 SI SI200731438T patent/SI2118074T1/sl unknown
- 2007-02-01 CN CN2007800523498A patent/CN101641339B/zh active Active
- 2007-02-01 NZ NZ579355A patent/NZ579355A/en unknown
- 2007-02-01 MX MX2009008099A patent/MX2009008099A/es active IP Right Grant
-
2010
- 2010-03-22 HK HK10102977.1A patent/HK1136283A1/xx unknown
-
2011
- 2011-09-23 US US13/243,776 patent/US8889698B2/en active Active
-
2014
- 2014-03-21 CY CY20141100220T patent/CY1115236T1/el unknown
- 2014-10-14 US US14/513,281 patent/US9199990B2/en active Active
-
2015
- 2015-10-26 US US14/922,645 patent/US20160106750A1/en not_active Abandoned
-
2017
- 2017-09-20 US US15/710,200 patent/US10532054B2/en active Active
-
2019
- 2019-12-09 US US16/707,559 patent/US20200352946A1/en not_active Abandoned
-
2021
- 2021-06-01 US US17/335,960 patent/US20210361656A1/en active Pending
Patent Citations (1)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
EP0210342A2 (de) * | 1985-05-03 | 1987-02-04 | Dr. Karl Thomae GmbH | Arzneimittel, enthaltend Pyridinone mit antithrombotischer Wirkung |
Cited By (2)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US10131640B2 (en) | 2009-03-18 | 2018-11-20 | Resverlogix Corp. | Anti-inflammatory agents |
US10111885B2 (en) | 2015-03-13 | 2018-10-30 | Resverlogix Corp. | Compositions and therapeutic methods for the treatment of complement-associated diseases |
Also Published As
Similar Documents
Publication | Publication Date | Title |
---|---|---|
CN101641339B (zh) | 用于预防和治疗心血管疾病的化合物 | |
CN102458405B (zh) | 新抗炎剂 | |
US9315521B2 (en) | Pyrimidines as novel therapeutic agents | |
CN102892759B (zh) | 具有犬尿氨酸产生抑制作用的含氮杂环化合物 | |
KR102057877B1 (ko) | 질소함유 헤테로고리 유도체 및 그의 약물에서의 용도 | |
CN1759114B (zh) | 作为细胞因子抑制剂的杂环n-芳基甲酰胺 | |
CN108516958B (zh) | 稠环衍生物、其制备方法、中间体、药物组合物及应用 | |
JP5369093B2 (ja) | 細胞保護作用を有するピリミジン誘導体およびその用途 | |
WO2007081978A2 (en) | Modulators of hepatocyte growth factor / c-met activity | |
CN103534241A (zh) | Fak抑制剂 | |
US11370803B2 (en) | Heteroaryl plasma kallikrein inhibitors | |
CN103319408B (zh) | 用于预防和治疗心血管疾病的化合物 | |
CN111909133A (zh) | 作为布鲁诺酪氨酸激酶抑制剂的取代的1-氨基-1h-咪唑-5-甲酰胺 |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
C06 | Publication | ||
PB01 | Publication | ||
C10 | Entry into substantive examination | ||
SE01 | Entry into force of request for substantive examination | ||
REG | Reference to a national code |
Ref country code: HK Ref legal event code: DE Ref document number: 1136283 Country of ref document: HK |
|
C14 | Grant of patent or utility model | ||
GR01 | Patent grant | ||
REG | Reference to a national code |
Ref country code: HK Ref legal event code: GR Ref document number: 1136283 Country of ref document: HK |
|
PE01 | Entry into force of the registration of the contract for pledge of patent right |
Denomination of invention: Compounds for the prevention and treatment of cardiovascular diseases Effective date of registration: 20220629 Granted publication date: 20130717 Pledgee: Hiprecy (Hong Kong) Ltd. Pledgor: RESVERLOGIX Corp. Registration number: Y2022990000387 |
|
PE01 | Entry into force of the registration of the contract for pledge of patent right |